VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: “COOL”), (OTCQB: “CLABF”), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted…

Source

Previous articlePT331 – Julie Zukof & Dr. Michelle Weiner – Psychedelic Women, Coaching, and Ketamine For Fibromyalgia
Next articleDiamond Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Low-Dose Psilocybin